Mariel B Deutsch1, Li-Jung Liang2, Elvira E Jimenez1, Michelle J Mather1, Mario F Mendez1. 1. Department of Neurology, David Geffen School of Medicine,University of California,Los Angeles,California,USA. 2. Medicine Statistics Core,David Geffen School of Medicine,University of California,Los Angeles, California,USA.
Abstract
BACKGROUND: Clinical research studies of behavioral variant frontotemporal dementia (bvFTD) often use Alzheimer disease (AD) as a comparison group for control of dementia variables, using tests of cognitive function to match the groups. These two dementia syndromes, however, are very different in clinical manifestations, and the comparable severity of these dementias may not be reflected by commonly used cognitive scales such as the Mini-Mental State Examination (MMSE). METHODS: We evaluated different measures of dementia severity and symptoms among 20 people with bvFTD compared to 24 with early-onset AD. RESULTS: Despite similar ages, disease-duration, education, and cognitive performance on two tests of cognitive function, the MMSE and the Montreal Cognitive Assessment (MoCA), the bvFTD participants, compared to the AD participants, were significantly more impaired on other measures of disease severity, including function (Functional Assessment Questionnaire (FAQ)), neuropsychiatric symptoms (Neuropsychiatric Inventory (NPI)), and global dementia stage (Clinical Dementia Rating Scales (CDRs)). However, when we adjusted for the frontotemporal lobar degeneration-CDR (FTLD-CDR) in the analyses, the two dementia groups were comparable across all measures despite significant differences on the cognitive scales. CONCLUSION: We found tests of cognitive functions (MMSE and MoCA) to be insufficient measures for ensuring comparability between bvFTD and AD groups. In clinical studies, the FTLD-CDR, which includes additional language and behavior items, may be a better overall way to match bvFTD and AD groups on dementia severity.
BACKGROUND: Clinical research studies of behavioral variant frontotemporal dementia (bvFTD) often use Alzheimer disease (AD) as a comparison group for control of dementia variables, using tests of cognitive function to match the groups. These two dementia syndromes, however, are very different in clinical manifestations, and the comparable severity of these dementias may not be reflected by commonly used cognitive scales such as the Mini-Mental State Examination (MMSE). METHODS: We evaluated different measures of dementia severity and symptoms among 20 people with bvFTD compared to 24 with early-onset AD. RESULTS: Despite similar ages, disease-duration, education, and cognitive performance on two tests of cognitive function, the MMSE and the Montreal Cognitive Assessment (MoCA), the bvFTDparticipants, compared to the ADparticipants, were significantly more impaired on other measures of disease severity, including function (Functional Assessment Questionnaire (FAQ)), neuropsychiatric symptoms (Neuropsychiatric Inventory (NPI)), and global dementia stage (Clinical Dementia Rating Scales (CDRs)). However, when we adjusted for the frontotemporal lobar degeneration-CDR (FTLD-CDR) in the analyses, the two dementia groups were comparable across all measures despite significant differences on the cognitive scales. CONCLUSION: We found tests of cognitive functions (MMSE and MoCA) to be insufficient measures for ensuring comparability between bvFTD and AD groups. In clinical studies, the FTLD-CDR, which includes additional language and behavior items, may be a better overall way to match bvFTD and AD groups on dementia severity.
Entities:
Keywords:
Alzheimer disease; behavioral and psychological symptoms of dementia; frontotemporal dementia; neuropsychiatric symptoms; research design and methodology
Authors: Breda Cullen; Brian O'Neill; Jonathan J Evans; Robert F Coen; Brian A Lawlor Journal: J Neurol Neurosurg Psychiatry Date: 2006-12-18 Impact factor: 10.154
Authors: Howard J Rosen; Jenille M Narvaez; Brad Hallam; Joel H Kramer; Christina Wyss-Coray; Rosalie Gearhart; Julene K Johnson; Bruce L Miller Journal: Alzheimer Dis Assoc Disord Date: 2004 Oct-Dec Impact factor: 2.703
Authors: K Rascovsky; D P Salmon; A M Lipton; J B Leverenz; C DeCarli; W J Jagust; C M Clark; M F Mendez; D F Tang-Wai; N R Graff-Radford; D Galasko Journal: Neurology Date: 2005-08-09 Impact factor: 9.910
Authors: David S Knopman; Joel H Kramer; Bradley F Boeve; Richard J Caselli; Neill R Graff-Radford; Mario F Mendez; Bruce L Miller; Nathaniel Mercaldo Journal: Brain Date: 2008-10-01 Impact factor: 13.501
Authors: Katya Rascovsky; John R Hodges; David Knopman; Mario F Mendez; Joel H Kramer; John Neuhaus; John C van Swieten; Harro Seelaar; Elise G P Dopper; Chiadi U Onyike; Argye E Hillis; Keith A Josephs; Bradley F Boeve; Andrew Kertesz; William W Seeley; Katherine P Rankin; Julene K Johnson; Maria-Luisa Gorno-Tempini; Howard Rosen; Caroline E Prioleau-Latham; Albert Lee; Christopher M Kipps; Patricia Lillo; Olivier Piguet; Jonathan D Rohrer; Martin N Rossor; Jason D Warren; Nick C Fox; Douglas Galasko; David P Salmon; Sandra E Black; Marsel Mesulam; Sandra Weintraub; Brad C Dickerson; Janine Diehl-Schmid; Florence Pasquier; Vincent Deramecourt; Florence Lebert; Yolande Pijnenburg; Tiffany W Chow; Facundo Manes; Jordan Grafman; Stefano F Cappa; Morris Freedman; Murray Grossman; Bruce L Miller Journal: Brain Date: 2011-08-02 Impact factor: 13.501
Authors: Carol Gregory; Sinclair Lough; Valerie Stone; Sharon Erzinclioglu; Louise Martin; Simon Baron-Cohen; John R Hodges Journal: Brain Date: 2002-04 Impact factor: 13.501
Authors: Sylvia S Fong; Pongsatorn Paholpak; Madelaine Daianu; Mariel B Deutsch; Brandalyn C Riedel; Andrew R Carr; Elvira E Jimenez; Michelle M Mather; Paul M Thompson; Mario F Mendez Journal: Cortex Date: 2017-04-08 Impact factor: 4.027
Authors: Toji Miyagawa; Danielle Brushaber; Jeremy Syrjanen; Walter Kremers; Julie Fields; Leah K Forsberg; Hilary W Heuer; David Knopman; John Kornak; Adam Boxer; Howard J Rosen; Bradley F Boeve; Brian Appleby; Yvette Bordelon; Jessica Bove; Patrick Brannelly; Christina Caso; Giovanni Coppola; Reilly Dever; Christina Dheel; Bradford Dickerson; Susan Dickinson; Sophia Dominguez; Kimiko Domoto-Reilly; Kelley Faber; Jessica Ferrell; Ann Fishman; Jamie Fong; Tatiana Foroud; Ralitza Gavrilova; Debra Gearhart; Behnaz Ghazanfari; Nupur Ghoshal; Jill S Goldman; Jonathan Graff-Radford; Neill Graff-Radford; Ian Grant; Murray Grossman; Dana Haley; Robin Hsiung; Edward Huey; David Irwin; David Jones; Lynne Jones; Kejal Kantarci; Anna Karydas; Daniel Kaufer; Diana Kerwin; Ruth Kraft; Joel Kramer; Walter Kukull; Irene Litvan; Diane Lucente; Codrin Lungu; Ian Mackenzie; Miranda Maldonado; Masood Manoochehri; Scott McGinnis; Emily McKinley; Mario F Mendez; Bruce Miller; Namita Multani; Chiadi Onyike; Jaya Padmanabhan; Alexander Pantelyat; Rodney Pearlman; Leonard Petrucelli; Madeline Potter; Rosa Rademakers; Eliana M Ramos; Kate Rankin; Katya Rascovsky; Erik D Roberson; Emily Rogalski; Pheth Sengdy; Leslie Shaw; Maria C Tartaglia; Nadine Tatton; Joanne Taylor; Arthur Toga; John Q Trojanowski; Ping Wang; Sandra Weintraub; Bonnie Wong; Zbigniew Wszolek Journal: Alzheimers Dement Date: 2020-01 Impact factor: 21.566